Document text
Principal Investigator: VICTORIA COLEMAN
Organization: LEIDOS BIOMEDICAL RESEARCH, INC.
Fiscal Year: 2023
Award: $7,090,787
Funding agency: National Institute of Allergy and Infectious Diseases
The NIAID mission and scope includes rapidly responding to infectious disease outbreaks through research, development, and clinical testing of vaccines and therapeutics for emerging and endemic infectious diseases. In 2019, in response to the COVID-19 outbreak, mRNA vaccines were quickly developed and evaluated clinically, leading to the eventual FDA-licensure of 2 vaccines used in the prevention of COVID 19. Part of that quick response included rapid manufacturing of nucleic acid (DNA and RNA) to support reagent and vaccine manufacturing and testing, which would be amendable for multiple infectious diseases such as HIV, CoV, Influenza, RSV, among other diseases.
Additionally, the LNP formulations developed would support mRNA-LNP encapsulated vaccines for multiple infectious diseases, including but not limited to HIV, CoV, Influenza, and access to clinically available lipid nanoparticle (LNP) formulations would enable low risk acceleration of vaccine formulations safe for human use.
Terms: <AIDS Virus><Acceleration><Acquired Immune Deficiency Syndrome Virus><Acquired Immunodeficiency Syndrome Virus><COVID-19 outbreak><COVID-19 prevention><COVID19 outbreak><COVID19 prevention><Clinical><Clinical Evaluation><Clinical Testing><Communicable Diseases><Coronaviridae><Coronavirus><DNA><Deoxyribonucleic Acid><Development><Disease><Disease Outbreaks><Disorder><Encapsulated><Formulation><Grippe><HIV><Human><Human Immunodeficiency Viruses><Infectious Disease Pathway><Infectious Diseases><Infectious Disorder><Influenza><LAV-HTLV-III><Licensure><Lipids><Lymphadenopathy-Associated Virus><Messenger RNA><Mission><Modern Man><NIAID><National Institute of Allergy and Infectious Disease><Non-Polyadenylated RNA><Nucleic Acids><Outbreaks><RNA><RNA Gene Products><RNA vaccine><RNA-based vaccine><Reagent><Research><Ribonucleic Acid><Risk><SARS-CoV-2 outbreak><Severe acute respiratory syndrome coronavirus 2 outbreak><Testing><Therapeutic><Vaccines><Virus-HIV><clinical test><corona virus><coronavirus disease 2019 outbreak><coronavirus disease 2019 prevention><coronavirus disease-19 outbreak><coronavirus disease-19 prevention><develop a vaccine><develop vaccines><development of a vaccine><developmental><evaluate vaccines><lipid based nanoparticle><lipid nanoparticle><mRNA><mRNA vaccine><mRNA-based vaccine><manufacture><novel><outbreak of SARS-CoV-2><prevent COVID-19><prevent COVID19><prevent coronavirus disease 2019><research clinical testing><response><tech development><technology development><vaccine development><vaccine evaluation><vaccine formulation><vaccine screening><vaccine testing>